Radioimmunotherapy of Metastatic Disease - Studies of Alpha- and Beta-particle-Emitting Radionuclides in a Preclinical Model
Author
Summary, in English
The results show that the tumor response was dose dependent after treatment with 177Lu-mAbs alone. Both evaluated activities of 211At-mAbs resulted in similar tumor response rate as the highest tested activity of 177Lu-mAbs (400 MBq/kg). Metastases were detected in approximately half the animals, regardless of the radionuclide or administered activity. The toxicity was deemed tolerable as the numbers of white blood cells and platelets recovered to initial levels.
Administration of the minimal effective activity of 177Lu-mAbs followed by treatment with unlabeled mAbs, 177Lu-mAbs, or 211At-mAbs resulted in a small increase in the number of tumors showing complete response. No effect was seen on the development of metastases. The additional treatment with unlabeled mAbs did not show any toxic effects. Repeated treatment with 177Lu-mAbs resulted in a prolonged period of low white blood cell counts and a second decrease in platelet counts. Sequential administration of minimal effective activities of first 177Lu-mAbs and then 211At-mAbs also resulted in prolonged myelotoxicity, but with faster recovery of the white blood cells than following the repeated treatment with 177Lu-mAbs.
Studies on the intratumoral distribution of the radioimmunoconjugates are important for our understanding of the response to treatment. The results showed that the activity was initially located in the tumor margins, and did not reach the more central parts until 24 h after administration. The distribution of activity was heterogeneous despite the expression of the antigen on all tumor cells. The tumor histology changed from dense tumor growth to areas of stromal tissue in some tumors after 24 h, while other tumors continued to grow. Calculations of the dose rate indicate that the tumors are treated most efficiently during the first 24 h after injection.
In summary, these results show that single treatment with alpha- and beta-particle-emitting radionuclides results in comparable toxicity at activities giving the same rate of tumor response. The studies on combined treatment showed that although a higher number of tumors showed complete response, there was no effect on the development of metastatic disease or survival.
Department/s
- Breastcancer-genetics
- BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
Publishing year
2013
Language
English
Publication/Series
Lund University Faculty of Medicine Doctoral Dissertation Series
Volume
2013:52
Full text
Document type
Dissertation
Publisher
Lund University: Faculty of Medicine
Topic
- Cancer and Oncology
Keywords
- Radioimmunotherapy
- Antibody therapy
- Lutetium-177
- Astatine-211
- Syngeneic tumor model
- Colon carcinoma
- Metastases
- Autoradiography
Status
Published
Supervisor
- Jan Tennvall
- Rune Nilsson
ISBN/ISSN/Other
- ISSN: 1652-8220
- ISBN: 978-91-87449-22-2
Defence date
23 May 2013
Defence time
09:00
Defence place
Alwall Lecture Hall, Barng 2A, Lund
Opponent
- Øyvind Bruland (Professor)